Autoantibodies and their clinical significance in idiopathic inflammatory myopathies; polymyositis/dermatomyositis and related conditions

Japanese Journal of Clinical Immunology

Volumn 30, Issue 6, 2007, Pages 444-454

  Hirakata, Michito ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aminoacyl tRNA synthetase; Autoantibodies; Interstitial lung disease; Myositis specific autoantibodies; Polymyositis dermatomyositis

Indexed keywords

AUTOANTIBODY;

DERMATOMYOSITIS; HUMAN; IMMUNOLOGY; REVIEW;

AUTOANTIBODIES; DERMATOMYOSITIS; HUMANS;

EID: 40349091732     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.30.444     Document Type: Article

References (64)

1. Reichlin, M. & Arnett, F. C.: Multiplicity of antibodies in myositis sera. Arthritis Rheum. 27: 1150–1156, 1984.
2. Love, L. A., et al.: A new approach to the classification of idiopathic inflammatory myopathy: Myositis-speciic autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70: 360–374, 1991.
3. Targoff, I. N.: Laboratory testing in the diagnosis and management of idiopathic inlammatory myopathies. Rheum. Dis. Clin.N.Am. 28: 859–890, 2002.
4. Mimori, T.: Autoantibodies in idiopathic inlammatory myopathy: An update on clinical and pathophysiological signiicance. Curr. Opin. Rheumatol. 19: 523–529, 2007.
5. Nishikai, M. & Reichlin, M.: Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis: Characterization of the Jo-1 antibody system. Arthritis Rheum. 23: 881–888, 1980.
6. his-containing antigen is recognized by the polymyositis-specific anti-Jo-1. Nucleic Acid Res. 11: 853–870, 1983.
7. Mathews, M. B. & Bernstein, R. M.: Myositis autoantibody inhibits histidyl-tRNA synthetase: A model for autoimmunity. Nature 304: 177–179, 1983.
8. Mathews, M. B. et al.: Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J. Exp. Med. 160: 420–434, 1984.
9. ala coexist and are associated with myositis. J. Exp. Med. 163: 1281–1291, 1986.
10. Targof, I. N.: Autoantibodies to aminoacyl-transfer RNA synthetase for isoleucine and glycine: Two additional synthetases are antigenic in myositis. J. Immunol. 144: 1737–1743, 1990.
11. Hirakata, M. et al.: Anti-KS: Identiication of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J. Immunol. 162: 2315–2320, 1999.
12. Betteridge, Z., et al.: Anti-synthetase syndrome: A new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 46: 1005–1008, 2007.
13. Hashish, L., et al.: Identiication of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome [abstract]. Arthritis Rheum. 52: S312, 2005.
14. Yoshida, S. et al.: The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 26: 604–611, 1983.
15. Hirakata, M. et al.: Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inlammatory muscle disease. Arthritis Rheum. 35: 449–456, 1992.
16. Marguerie, C. et al.: Polymyositis, pulmonary ibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q. J. Med. 77: 1019–1038, 1990.
17. Jofe, M. M. et al.: Drug therapy of the idiopathic inlammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am. J. Med. 94: 379–387, 1993.
18. Hirakata, M. & Nagai, S.: Interstitial lung disease in polymyositis and dermatomyositis. Curr. Opin. Rheumatol. 12: 501–508, 2000.
19. Oddis, C. V., Medsger, T.A. Jr, Cooperstein, A.: A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum. 33: 1640–1645, 1990.
20. Mitra, D., et al.: Clinical and histological features of ’mechanic's hands’ in a patient with antibodies to Jo-1 -a case report. Clin. Exp. Dermatol. 19: 146–148, 1994.
21. Friedman, A. W. et al.: Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetase in the absence of clinically apparent myositis. Semin. Arthritis Rheum. 26: 459–467, 1996.
22. Hirakata, M. et al.: Anti-alanyl tRNA synthetase (PL-12) antibodies are associated with interstitial lung disease in Japanese patients [abstract]. Arthritis Rheum. 38: S321, 1995.
23. Hirakata, M., et al.: Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum. 56: 1295–1303, 2007.
24. Katsuki, Y., et al.: Anti-glycyl tRNA synthetase antibodies are associated with interstitial lung disease and dermatomyositis in Japanese patients [abstract]. Arthritis Rheum. 54: S663, 2006.
25. Sato, S., et al.: Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin. Exp. Rheumatol. 23: 609–615, 2005.
26. Yamasaki, Y., et al.: Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum. 54: 2004–2009, 2006.
27. Casciola-Rosen, L., et al.: Cleavage by granzyme B is strongly predictive of autoantigen status: Implications for initiation of autoimmunity. J. Exp. Med. 190: 815–826, 1999.
28. Howard, O. M., et al.: Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J. Exp. Med. 196: 781–791, 2002.
29. Plotz, P. H.: The autoantibody repertoire: Searching for order. Nat. Rev. Immunol. 3(1): 73–78, 2003.
30. Casciola-Rosen, L., et al.: Enhanced autoantigen expression in regenerating muscle cells in idiopathic inlammatory myopathy. J. Exp. Med. 201: 591–601, 2005.
31. Levine, S. M., et al.: Novel conformation of histidyl-transfer RNA synthetase in the lung. The target in Jo-1 autoantibodies-associated myositis. Arthritis Rheum. 56: 2729–2739, 2007.
32. Walter, P., Lingappa, V.R.: Mechanismof protein translocation across the endoplasmic reticulum membrane. Annu. Rev. Cell Biol. 2: 499–516, 1986.
33. Targof, I. N., Johnson, A. E., Miller, F. W.: Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 33: 1361–1370, 1990.
34. Satoh, T., et al.: Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis. J. Rheumatol. 32: 1717–1733, 2005.
35. Hirakata, M., et al. Immunological and histopathological features of patients with anti-SRP autoantibodies [abstract]. Arthritis Rheum. 40: S146, 1997.
36. Arlet, J. B., et al.: Marked eicacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul. Disord. 16: 334–336, 2006.
37. Hengstman, G. J., et al.: Anti-signal recognition particle autoantibodies: Marker of a necrotising myopathy. Ann. Rheum. Dis. 65: 1635–1638, 2006.
38. Kao, A. H., et al.: Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 50: 209–215, 2004.
39. Hirakata, M., et al.: Heterogeneity of autoimmune responses to the signal recognition particle (SRP): Clinical associations in Japanese patients [abstract]. Arthritis Rheum. 54: S664, 2006.
40. Targoff, I. N., Hanas, J.: The polymyositis-associated Fer antigen is elongation factor 1α [abstract]. Arthritis Rheum. 32: S81, 1989.
41. Hirakata, M., et al.: Clinical and immunological features in patients with anti-Fer (Elongation factor 1 alpha) autoantibodies [abstract]. Arthritis Rheum. 48: S103, 2003.
42. Ohkouchi, K., et al.: Anti-elongation factor- alpha autoantibody in adult atopic dermatitis patients. Int. Immunol. 11: 1635–1640, 1999.
43. Bernstein, R. M., et al.: Cellular protein and RNA antigens in autoimmune disease. Mol. Biol. Med. 2: 105–120, 1984.
44. Targoff, I. N. L., et al.: Anti-KJ: A new antibody associated with myositis/lung syndrome that reacts with a translation-related protein. J. Clin. Invest. 84: 162–172, 1989.
45. Seeling, HP., et al.: Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum. 39: 1769–1771, 1996.
46. Zhang, Y., et al.: The dermatomyositis-specific autoantigen Mi-2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 95: 279–289, 1998.
47. Targof, I. N., Reichlin, M.: The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 28: 796–803, 1985.
48. Mierau, R., et al.: Strong association of dermatomyositis-speciic Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum. 39: 868–876, 1996.
49. Okada, S., et al.: Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 48: 2285–2293, 2003.
50. Gottlieb, T. M., Jackson, S. P.: The DNA-dependent protein kinase. Requirement for DNA ends and association with Ku antigen. Cell 72: 131–142, 1993.
51. Hirakata, M., et al.: Association between autoantibodies to the Ku protein and DPB1. Arthritis Rheum. 52: 608–609, 2005.
52. Suwa, A., et al.: Autoantibodies to DNA-dependent protein kinase. Probes for the catalytic subunit. J. Clin. Invest. 97: 1417–1421, 1996.
53. Takeda, Y., et al.: Enzyme-linked immunosorbent assay using isolated (U) small nuclear ribonucleoprotein polypeptides as antigens to investigate the clinical signiicance of autoantibodies to these polypeptides. Clin. Immunol. Immunopathol. 50: 213–230, 1989.
54. Craft, J., et al.: The U2 small nuclear ribonucleoprotein particle as an autoantigen. Analysis with sera from patients with overlap syndromes. J. Clin. Invest. 81: 1716–1724, 1987.
55. Oddis, C. V., et al.: Serum autoantibody to the nucleolar antigen PM-Scl: Clinical and immunogenetic associations. Arthritis Rheum. 35: 1211–1217, 1992.
56. Sato, S., et al.: Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52: 1571–1576, 2005.
57. Casciola-Rosen, L. A., et al.: The DNA mismatch repair enzyme PMS1 is a myositis-speciic autoantigen. Arthritis Rheum. 44: 389–396, 2001.
58. Hirakata, M., et al.: Clinical and immunological features in Japanese patients with anti-PMS1 autoantibodies [abstract]. Arthritis Rheum. 50: S100, 2004.
59. Oddis, C. V., et al.: Clinical and serological characterization of the anti-MJ antibody in childhood myositis. Arthritis Rheum. 40: S139, 1997.
60. Targof, I. N., et al.: Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum. 56: S787, 2007.
61. Targoff, I. N., et al.: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 54: 3682–3689, 2006.
62. Targoff, I. N., et al.: Autoantibodies to transcriptional intermediary factor-1 gamma (TIF-1γ) in dermatomyositis [abstract]. Arthritis Rheum. 54: S518, 2006.
63. Kaji, K., et al.: Identiication of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: An association with malignancy. Rheumatology 46: 25–28, 2007.
64. Betteridge, Z., et al.: Identiication of a novel autoantibody directed against small ubiquitinlike modiier activating enzyme in dermatomyositis. Arthritis Rheum. 56: 3132–3137, 2007.